Fellow Eye Anti-VEGF ‘Crunch’ Effect in Retinopathy of Prematurity

BACKGROUND AND OBJECTIVE: Anti-vascular endothelial growth factor (VEGF) therapy is increasing in popularity for treatment of retinopathy of prematurity (ROP). Despite many technical benefits, issues remain prompting further investigation. PATIENTS AND METHODS: Retrospective case report and literature review. RESULTS: A 42-week-old postmenstrual age female with gestational age of 28 weeks and birth weight of 990 g presented with prominent progression of peripapillary purely tractional atypical stage 4A ROP in both eyes following intravitreal bevacizumab therapy in the right eye only. CONCLUSION: The authors present the first reported case, to their knowledge, of a “crunch” phenomenon tractional retinal detachment from fellow eye administration of bevacizumab. [ Ophthalmic Surg Lasers Imaging Retina . 2018;49:e102–e104.]